Online citations, reference lists, and bibliographies.
← Back to Search

Paclitaxel By 3-hour Infusion In Combination With Bolus Doxorubicin In Women With Untreated Metastatic Breast Cancer: High Antitumor Efficacy And Cardiac Effects In A Dose-finding And Sequence-finding Study.

L. Gianni, E. Munzone, G. Capri, F. Fulfaro, E. Tarenzi, F. Villani, C. Spreafico, A. Laffranchi, A. Caraceni, C. Martini
Published 1995 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To define the maximum-tolerated dose (MTD) and better tolerated sequence of paclitaxel by 3-hour infusion plus bolus doxorubicin (DOX) and to evaluate antitumor efficacy. PATIENTS AND METHODS Thirty-five women with metastatic breast cancer (dominant visceral metastases in 56%, and involvement of > or = three sites in 67%) who never received chemotherapy of any type were studied. Paclitaxel every 3 weeks (125 mg/m2 starting dose) was increased by 25-mg/m2 steps in subsequent cohorts of patients. DOX (60 mg/m2 fixed dose) was administered 15 minutes before the start of or after the end of paclitaxel for a maximum of eight cycles. Subsequently, patients in continuous response could receive single-agent paclitaxel (175 to 200 mg/m2 every 3 weeks). The drug sequence was alternated in consecutive patients and in the first two cycles. RESULTS Severe neutropenia that lasted greater than 7 days (n = 4), febrile neutropenia (n = 7) and grade III oral mucositis (n = 6) defined the MTD of paclitaxel at 200 mg/m2 in 34 assessable patients. Grade II peripheral neuropathy occurred in 33% of patients. Six women (18%) developed clinically reversible congestive heart failure (CHF) after a median of 480 mg/m2 total DOX. Drug sequence had no effect on toxicities. High efficacy on all metastatic sites in 32 assessable patients accounted for a 41% complete response (CR) rate (95% confidence interval [CI], 24% to 59%) and 94% overall-response rate (95% CI, 79% to 99%). After a median follow-up of 12 months (range 3 to 18), the median response duration is 8 months (range, 2+ to 18+) for complete responders and 11 months (range 1+ to 15+) for partial responders. CONCLUSION The rate of CR and incidence of CHF may be an expression of therapeutic and toxic enhancement due to the schedule used in this trial. Until clarification of this possibility, this promising combination should be used in investigational trials.



This paper is referenced by
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
K. Bhalla (1999)
Vinorelbine a nd P aclitaxel a s F irst-Line C hemotherapy in M etastatic B reast C ancer
M. Langhi (1999)
10.1185/030079901750176726
A Phase II Trial of Fractionated Vinorelbine/Doxorubicin as First-line Therapy for Advanced Breast Cancer
R. Hegg (2000)
10.1200/JCO.1999.17.1.74
Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer.
L. R. Romero Acuña (1999)
Tools for decoding the structure-function relationships of biopolymers in nanotechnology and glycobiology
Venkataramanan Soundararajan (2010)
10.1038/sj.bmt.1702449
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function
M. Rose (2000)
10.1007/s00280-003-0690-0
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
S. Morales (2003)
10.1200/JCO.2002.11.005
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
L. Biganzoli (2002)
10.1634/THEONCOLOGIST.6-SUPPL_3-5
Taxane/anthracycline combinations: setting a new standard in breast cancer?
J. Nabholtz (2001)
10.1016/S0959-8049(96)00407-8
Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure.
M. Colleoni (1997)
10.1093/eurheartj/ehw211
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
J. Zamorano (2016)
10.1200/JCO.2005.08.789
Cardiotoxicity of cancer therapy.
Justin D. Floyd (2005)
10.1042/CS20120620
Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
Hardip Sandhu (2014)
10.1016/S0090-4295(99)00451-3
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
U. Vaishampayan (1999)
10.3816/CBC.2009.n.027
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
R. Yerushalmi (2009)
10.1016/S0378-6080(10)32045-9
Cytostatic and cytotoxic drugs
A. Sabharwal (2010)
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
S. Giordano (2002)
10.1185/0300799019117001
A Phase II Trial of Fractionated Vinorelbine/Doxorubicin as First-line Therapy for Advanced Breast Cancer
R. Hegg (2001)
10.1200/JCO.2005.12.106
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
C. Zielinski (2005)
10.1016/S0959-8049(00)00012-5
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
P. Katsimbri (2000)
10.1159/000011977
A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer
R. Lauria (1999)
10.1200/JCO.2001.19.5.1256
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
A. Taamma (2001)
10.1016/J.BREAST.2004.02.007
Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
A. Tiersten (2004)
A Phase II Study of Genexol® ( paclitaxel ) in Metastatic Breast Cancer
J. Y. Jung (2001)
10.1016/S0093-7754(01)90195-2
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
V. Valero (2001)
10.3816/CBC.2002.N.035
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
C. Hudis (2002)
10.1200/JCO.2001.19.8.2222
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
G. Grasselli (2001)
Cardiac adverse events associated with antineoplastic treatment in elderly cancer patients
K. Soter (2012)
10.1016/S1053-4296(97)80061-6
Clinical pharmacology of taxanes as radiosensitizers and the thiol-based radioprotectant amifostine
Robert T. Dorr (1997)
10.2165/00002018-199615060-00005
A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy
R. Abraham (1996)
10.1200/JCO.1996.14.3.774
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
J. Fisherman (1996)
10.1007/978-1-4899-0218-4_20
Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds
E. K. Rowinsky (1996)
See more
Semantic Scholar Logo Some data provided by SemanticScholar